Cytokeratin 19 Fragment (CYFRA21-1) Predicts the Efficacy of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) in Non-Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutation

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Cytokeratin 19 ◽

Small Cell Lung ◽

Epidermal Growth ◽

Cytokeratin 19 Fragment ◽

Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor in Non–Small-Cell Lung Cancer Harboring EGFR Mutation

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e31828c3929 ◽

2013 ◽

Vol 8 (7) ◽

pp. 892-898 ◽

Cited By ~ 24

Author(s):

Kosuke Tanaka ◽

Akito Hata ◽

Reiko Kaji ◽

Shiro Fujita ◽

Takehiro Otoshi ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Cytokeratin 19 ◽

Small Cell Lung ◽

Epidermal Growth ◽

Cytokeratin 19 Fragment

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor, in Patients with Platinum Refractory Non-small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000263712.61697.69 ◽

2007 ◽

Vol 2 (4) ◽

pp. 299-305 ◽

Cited By ~ 44

Author(s):

Shirish M. Gadgeel ◽

John C. Ruckdeschel ◽

Elisabeth I. Heath ◽

Lance K. Heilbrun ◽

Raghu Venkatramanamoorthy ◽

...

Keyword(s):

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Refractory ◽

Epidermal Growth ◽

Cox 2 ◽

The plasma ctDNA monitoring during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)

Annals of Oncology ◽

10.1093/annonc/mdy292.046 ◽

2018 ◽

Vol 29 ◽

pp. viii514

Author(s):

K. Usui ◽

T. Yokoyama ◽

A. Kisohara ◽

Y. Mori ◽

Y. Takeda ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Tki Treatment ◽

Egfr Mutant ◽

Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer

Drugs of Today ◽

10.1358/dot.2019.55.4.2965337 ◽

2019 ◽

Vol 55 (4) ◽

pp. 231 ◽

Cited By ~ 4

Author(s):

T. Nagano ◽

M. Tachihara ◽

Y. Nishimura

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e18062 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e18062-e18062

Author(s):

C. Tsai ◽

K. Chang ◽

C. Chiu ◽

S. Hsiao

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Epidermal Growth ◽

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

European Journal of Cancer ◽

10.1016/s0959-8049(02)80848-6 ◽

2002 ◽

Vol 38 ◽

pp. S62

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Platinum Based Chemotherapy ◽

Epidermal Growth ◽

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Lung Cancer ◽

10.1016/j.lungcan.2018.12.007 ◽

2019 ◽

Vol 128 ◽

pp. 6-12 ◽

Cited By ~ 5

Author(s):

Xiangtao Yan ◽

Huijuan Wang ◽

Peng Li ◽

Guowei Zhang ◽

Mina Zhang ◽

...

Keyword(s):

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Egfr Tki ◽

First Line Treatment

Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

10.1158/1538-7445.am2016-ct079 ◽

2016 ◽

Cited By ~ 1

Author(s):

Sai-Hong Ou ◽

Keunchil Park ◽

Ji-Youn Han ◽

Dong-Wan Kim ◽

Lyudmila Bazhenova ◽

...

Keyword(s):

Growth Factor ◽

Epidermal Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Smoking history, drug toxicity, and survival in non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) drugs

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.9570 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 9570-9570

Author(s):

M. E. Cooley ◽

K. M. Emmons ◽

H. Li ◽

D. P. Harrington ◽

D. C. Christiani ◽

...

Keyword(s):

Drug Toxicity ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Smoking History ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients ◽

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30299-4 ◽

2016 ◽

Vol 11 (4) ◽

pp. S139 ◽

Cited By ~ 11

Author(s):

K. Park ◽

J.-Y. Han ◽

D.-W. Kim ◽

L.A. Bazhenova ◽

S.-H. Ou ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽